<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1564">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04475991</url>
  </required_header>
  <id_info>
    <org_study_id>DI/20/407/04/38</org_study_id>
    <nct_id>NCT04475991</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults</brief_title>
  <acronym>COMVIVIR</acronym>
  <official_title>Phase2, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Maraviroc and/or Favipiravir Plus Standard Therapy in Adult Patients With Severe Non-critical COVID-19&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de México Dr. Eduardo Liceaga</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CCINSHAE. Secretaría de Salud. México</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Investigación en. Enfermedades Infecciosas, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General de México Dr. Eduardo Liceaga</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2, randomized, open-label study to evaluate the safety and efficacy of maraviroc,&#xD;
      favipiravir, and both drugs administered along with currently used therapy in hospitalized&#xD;
      patients with pulmonary SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)&#xD;
      infection (COVID-19)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The COVID-19 pandemic (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory&#xD;
      Syndrome Coronavirus 2) has caused more that 10 million infections worldwide, with a general&#xD;
      mortality of 6%. Multiple studies have found that the hyperinflammatory immune response&#xD;
      induced by SARS-CoV-2 is one of the main causes of severity and death in infected patients.&#xD;
      In severe COVID-19 patients, an association was found between pneumonitis and/or ARDS (Acute&#xD;
      Severe Respiratory Syndrome), increased serum levels of cytokines and chemokines, extensive&#xD;
      lung damage and microthrombosis. Studies of both gene expression in lungs and blood cytokines&#xD;
      and chemokines have related chemokine signaling clusters with COVID-19 severity, being CCL3,&#xD;
      CCL4 and CCL7 (CC chemokine ligands 3, 4 and 7) particularly interesting. All these are CCR5&#xD;
      (CC chemokine receptor 5) ligands. A strategy to modulate activation and trafficking of&#xD;
      leukocytes to the lungs is by blocking CCR5 by using maraviroc (MVC), which has shown capable&#xD;
      of modulating conditions of generalized inflammation. Along with a good regulation of the&#xD;
      immune response, an antiviral that helps to reduce the viral load must be considered.&#xD;
      Favipiravir (FPV) has shown to be capable to reduce the time of viral clearance by half.&#xD;
      Hence, we propose that the conjoint use of MVC and FPV could help to reduce the progression&#xD;
      of severe hospitalized COVID-19 patients to critical by decreasing the percentage of patients&#xD;
      in need of mechanical respiratory support or death by at least 30%. This is a randomized,&#xD;
      controlled clinical trial that besides evaluating the safety and efficacy of MVC+FPV to avoid&#xD;
      progression in severe COVID-19 patients as a primary endpoint, is also aimed at other&#xD;
      secondary endpoints: A) Evaluate the activation of CCR5 in peripheral blood lymphocytes,&#xD;
      monocytes, and neutrophils. B) Find possible modifications in the ongoing chemokine and&#xD;
      cytokine storm in serum, particularly IL-6, IL-1b, (interleukins 6 and 1 beta) TNF (tumor&#xD;
      necrosis factor), IFNa, IFNg (interferons alpha and gamma), VEGF (vascular endothelial growth&#xD;
      factor), CXCL10 (CXC chemokine ligand 10), CCL7, CCL3, and CCL5 (CC chemokine ligands 7, 3&#xD;
      and 5), C) Search for alterations in the patterns of activation, trafficking, and exhaustion&#xD;
      of peripheral blood lymphocytes, monocytes and neutrophils, and D) Determine if it has an&#xD;
      effect in viral loads in saliva. 100 severe patients tested positive for SARS-CoV-2 will be&#xD;
      randomized in 4 treatment arms:&#xD;
&#xD;
      Arm A: Currently used therapy (CT) only, Enoxaparin, dexamethasone, and antibiotics if&#xD;
      associated bacteremia is present, as per currently used at Hospital General de México &quot;Dr.&#xD;
      Eduardo Liceaga&quot;).&#xD;
&#xD;
      Arm B: CT+MVC Arm C: CT+FPV Arm D: CT+MVC+FPV&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>100 participants will be included and allocated in 4 groups of 25 each [Currently used therapy (CT), Maraviroc+CT, Favipiravir+CT and Maraviroc+Favipiravir+CT]. Subjects will be randomized using EPIDAT 4.2</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients free of mechanical ventilation or death</measure>
    <time_frame>28 days post start</time_frame>
    <description>Percentage of patients free of mechanical ventilation or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients free of mechanical ventilation or death</measure>
    <time_frame>5 days post start</time_frame>
    <description>Percentage of patients free of mechanical ventilation or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of clinical improvement</measure>
    <time_frame>15 days post start</time_frame>
    <description>Time of improvement in at least 2 items of the 7-item World Health Organization (WHO) ordinal scale for COVID-19 in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in phosphorylated CCR5</measure>
    <time_frame>Day 10-1</time_frame>
    <description>Rate of change (Delta) in lymphocytes, monocytes and neutrophils with phosphorylated CCR5 as per measured by parameters of flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in peripheral blood levels of proinflammatory cytokines and chemokines</measure>
    <time_frame>Day 10-1</time_frame>
    <description>Rate of change (Delta) in peripheral blood levels of proinflammatory cytokines and chemokines [IL-6, IL-1b, TNF, IFNa, IFNg, VEGF, GM-CSF (granulocyte-macrophage colony stimulating factor), CCL2, CCL3, CCL4, CCL5, CXCL10 and CCL7], as per measured by parameters of flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the trafficking and activation pattern of peripheral leukocytes</measure>
    <time_frame>Day 10-1</time_frame>
    <description>Statistically significant change in the expression of activation [phosphorylated CCR5,CD38, CD126, CD127, CD25, CD86, CD83, CD40 (clusters of differentiation 38, 126, 127, 25, 86 and 40), HLA-DR (Human Leukocyte Antigen-DR isotype), Granzyme B, Perforin, CD107A, CD123, gp130, CD95], trafficking [CCR5, CCR2, CCR6, CCR7, CXCR1, CXCR3 , CXCR5, (CXC chemokine receptors 1, 3 and 5), CX3CR1 (CX3C chemokine receptor] and exhaustion (PD1, programmed death-1 receptor) markers in peripheral blood lymphocytes, neutrophils and monocytes, as per measured by parameters of flow cytometry.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Currently used therapy (CT) only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment currently used at Hospital General de México &quot;Dr. Eduardo Liceaga&quot; for non-critical COVID patients: Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maraviroc+CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maraviroc AND treatment currently used at Hospital General de México &quot;Dr. Eduardo Liceaga&quot; for non-critical COVID patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Favipiravir+CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Favipiravir AND treatment currently used at Hospital General de México &quot;Dr. Eduardo Liceaga&quot; for non-critical COVID patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maraviroc+Favipiravir+CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maraviroc AND Favipiravir AND treatment currently used at Hospital General de México &quot;Dr. Eduardo Liceaga&quot; for non-critical COVID patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc + Currently used therapy</intervention_name>
    <description>Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México &quot;Dr. Eduardo Liceaga&quot;)</description>
    <arm_group_label>Maraviroc+CT</arm_group_label>
    <other_name>MVC+CT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Curently used therapy for COVID-19 non-critical patients</intervention_name>
    <description>Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México &quot;Dr. Eduardo Liceaga&quot;</description>
    <arm_group_label>Currently used therapy (CT) only</arm_group_label>
    <other_name>CT only</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir + Currently used therapy</intervention_name>
    <description>Favipiravir tablets 200 mg. given orally for a 7 day period. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México &quot;Dr. Eduardo Liceaga&quot;).</description>
    <arm_group_label>Favipiravir+CT</arm_group_label>
    <other_name>FPV+CT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc+Favipiravir+CT</intervention_name>
    <description>Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND Favipiravir tablets 200 mg. given orally for the first 7 days. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México &quot;Dr. Eduardo Liceaga&quot;&quot;)</description>
    <arm_group_label>Maraviroc+Favipiravir+CT</arm_group_label>
    <other_name>MVC+FPV+CT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  With severe non-critical stage of COVID at the time of admission.&#xD;
&#xD;
          -  Patients tested positive for SARS-CoV-2 confirmed by PCR (Polymerase Chain Reaction)&#xD;
&#xD;
          -  Within the first 12 days post appearance of symptoms&#xD;
&#xD;
          -  With at least one of the following risk factors: Diabetes mellitus (DM), obesity&#xD;
             (BMI&gt;30, hypertension, age &gt; 65 years.&#xD;
&#xD;
          -  Respiratory rate 25-34/min and no signs of respiratory distress.&#xD;
&#xD;
          -  Thorax USG with LUS (Lung Ultrasonographic Score)&gt;23&#xD;
&#xD;
          -  With at least two of the following indicators of severity: SpO2 81-90%, PaFi 250-100&#xD;
             mmHg, FiO2&gt;60% , LHD (Lactic Acid Dehydrogenase) &gt;350 U/L, lung infiltration &gt;50%&#xD;
             determined by thorax radiography.&#xD;
&#xD;
          -  Normal liver function (Considered up to a fivefold increase above the normal limits of&#xD;
             hepatic transaminases)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients already participating in another clinical study&#xD;
&#xD;
          -  Clinical evidence of an infectious disease different from COVID at the time of&#xD;
             admission&#xD;
&#xD;
          -  Signs of respiratory distress&#xD;
&#xD;
          -  Chronic kidney failure&#xD;
&#xD;
          -  Coronary disease&#xD;
&#xD;
          -  Glasgow score &lt; 13&#xD;
&#xD;
          -  Glomerular filtration rate &lt; 60ml/min/1.73 m2 and known history of preexisting chronic&#xD;
             renal failure (Chronic kidney disease stages 3,4,5)&#xD;
&#xD;
          -  Known history of HCV, HBV and/or clinical signs of hepatic liver failure.&#xD;
&#xD;
          -  Any type of cancer&#xD;
&#xD;
          -  HIV and/or any anti retroviral treatment&#xD;
&#xD;
          -  Psychotropics treatment&#xD;
&#xD;
          -  With transplant background&#xD;
&#xD;
          -  With any autoimmune disorder&#xD;
&#xD;
          -  With known hypersensibility to maraviroc and/or favipiravir&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María Luisa Hernández-Medel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital General de México Dr. Eduardo Liceaga</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adolfo Pérez-García, PhD</last_name>
    <phone>+52(55)27892000</phone>
    <phone_ext>1151</phone_ext>
    <email>aperezg@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joselin Hernández-Ruiz, PhD</last_name>
    <phone>+52(55)27892000</phone>
    <phone_ext>1385</phone_ext>
    <email>hernandezjoselin@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General de México &quot;Dr. Eduardo Liceaga&quot;</name>
      <address>
        <city>Mexico City</city>
        <state>Cdmx</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Adolfo Pérez-García, PhD</last_name>
      <phone>+52(55)27892000</phone>
      <phone_ext>1151</phone_ext>
      <email>aperezg@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Joselin Hernández-Ruiz, PhD</last_name>
      <phone>+52(55)27892000</phone>
      <phone_ext>1385</phone_ext>
      <email>hernandezjoselin@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de México Dr. Eduardo Liceaga</investigator_affiliation>
    <investigator_full_name>María Luisa Hernández-Medel</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>CCR5</keyword>
  <keyword>Cytokine storm</keyword>
  <keyword>Maraviroc</keyword>
  <keyword>Favipiravir</keyword>
  <keyword>RdRP inhibitors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Inter-institutional exchange of data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Information will be shared upon completion of the study for collaborative purposes</ipd_time_frame>
    <ipd_access_criteria>Upon request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

